Article thumbnail

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients

By Angelo Antonini and Daniela Calandrella

Abstract

Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation. This review summarized the pharmacokinetic profile of pramipexole for both the IR and ER formulations, and discussed the role of pramipexole in the management of early and advanced PD. The introduction of a once-daily formulation of pramipexole poses significant potential advantages for patients and this is reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course

Topics: Expert Opinion
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:3101890
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson’s disease.
  2. A double-blind, placebo-controlled, randomized, multicenter study of pramipexole in advanced Parkinson’s disease.
  3. (2006). A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther.
  4. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function.
  5. (1997). Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos.
  6. (1997). Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebocontrolled, parallel-group study.
  7. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease.
  8. Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson’s disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats.
  9. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease.
  10. Double-blind evaluation of pramipexole extended release (ER)
  11. (2003). double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. Mov Disord.
  12. (2010). double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord.
  13. (2009). Efficacy and safety of pramipexole extended-release for advanced Parkinson’s disease [abstract]. Mov Disord.
  14. (2009). Efficacy of pramipexole extended release (ER) and switching from pramipexole immediate release (IR) to ER
  15. efficacy of pramipexole in early Parkinson disease. A randomized dose1 ranging study.
  16. (1997). Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology.
  17. Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial.
  18. (2006). Minimal clinically important change on unified Parkinson’s disease rating scale. Mov Disord.
  19. (2009). Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther.
  20. (1998). Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson’s disease. Clin Neuropharmacol.
  21. Pramipexole extended release: a novel treatment option in Parkinson’s disease. Parkinsons Dis.
  22. (1995). Pramipexole in patients with early Parkinson’s disease. Clin Neuropharmacol.
  23. Pramipexole Switch Study Group. Efficacy, safety, and tolerability of overnight switching from immediate- to once daily extended-release pramipexole in early Parkinson’s disease.
  24. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
  25. Pre-clinical studies of pramipexole: clinical relevance.
  26. Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson’s disease.
  27. (1999). safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry.
  28. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.
  29. Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat brain.
  30. The effect of repeated treatment with pramipexole on the central dopamine D3 system.
  31. (2001). The long-term safety and efficacy of pramipexole in advanced Parkinson’s disease. Parkinsonism Relat Disord.
  32. The scientific and clinical basis for the treatment of Parkinson disease.
  33. (2005). Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos.
  34. (2010). Trocóniz IF. Population in vitro-in vivo correlation model for pramipexole slowrelease oral formulations. Pharm Res.